Jan Lilja, laboratory engineer, and Sven-Erik Nilsson, computer expert, of the Kristianstad Hospital Clinical Laboratory begin outlining an improved method for measuring hemoglobin.
The soundness of the method and the feasibility of microcuvette production are proven.
A license agreement with pharmaceutical company Leo is signed. Toward the end of the year, Lilja and Nilsson move into Leo's premises.
Leo begins selling and distributing the first hemoglobin photometers.
The hemoglobin system is successfully introduced on the US market. Turnover rises almost 80%.
Leo is purchased by Pharmacia.
Leo Diagnostics is bought out by the management and HemoCue AB is formed.
Acquisition of US Distributor - HemoCue Inc. is founded.
The glucose system, based on the same principles as the hemoglobin system, is introduced to the market.
HemoCue finds a new owner: Mallinckrodt Inc of Saint Louis, Missouri, USA.
The first HemoCue Academy takes place in Norrköping, Sweden.
HemoCue is acquired by EQT, a private equity group in northern Europe. Annual turnover exceeds $40 million.
A new system, HemoCue® Plasma/Low Hb System, is introduced. The system is used for determination of low hemoglobin levels in plasma, serum and aqueous solutions.
HemoCue® Donor Hb Checker, a system for measuring hemoglobin in blood donors, is introduced.
The HemoCue 201 System for glucose is introduced.
By introducing a Urine Albumin analyzer for detecting microalbuminuria, HemoCue enters yet another significant testing area.
The HemoCue 201 System for glucose is followed by a HemoCue® 201+ System for both glucose and hemoglobin making it possible to store test and QC results in the analyzer.
HemoCue makes extensive investments in production technology, R&D, Sales and Marketing. Acquisition of Biotest. Distribution agreements with McKesson and PSS.
HemoCue® Data Management Systems for glucose and hemoglobin are launched in Europe.
Market introduction of HemoCue® Home Glucose.
Market introduction of HemoCue® Albumin 201, HemoCue® Hb 301 and HemoCue® Glucose 201 RT.
HemoCue is acquired by Quest Diagnostics.
Market introduction of HemoCue® WBC, a system for determination of total white blood cell count. HemoCue® Albumin 201 System receives first FDA CLIA waiver in diagnostics industry for quantitative point-of-care test for microalbuminuria.
HemoCue® WBC DIFF is introduced. A system that provides a quantitative determination of white blood cells with a five part differential count of neutrophils, lymfocytes, monocytes, eosinphils and basophils. The same year, we also launch two additional systems with room temperature microcuvette storage - the HemoCue® 201 RT and HemoCue 201 RT DM System.
Another member to the diabetes portfolio is added with the launch of HemoCue® HbA1c 501 System. The new system is a fast, easy and reliable point-of-care system for hemoglobin A1c tests. It is a fully automated HbA1c POCT that provides reliable results at the point of care for efficient diabetes care.
HemoCue is acquired by Radiometer Medical Aps, a Danaher company, in April 2013. Additional company information about Danaher and Radiometer is available on below links:
HemoCue® HealthTrender Anemia is launched. It is a solution that assists you in the fight against anemia. It provides immediate insight through real time data to the program manager for instant review and monitoring of anemia programs.
We celebrate our 35th Anniversary at our headquarter in Ängelholm, Sweden. Our colleagues working at HemoCue offices around the world join us in the celebration.
Beginning of January, we announce launch of our innovative HemoCue® Hb 801 System - the latest addition to our hemoglobin portfolio. The analyzer provides lab-accurate results in less than one second and features a unique "Let-go-grip" for easier handling. In February we receive 510(k) clearance from the US Food and Drug Administration (USFDA) and the product is launched on the US market.